SCHEMBL1401236

SCHEMBL1401236

CCCCC([C]=O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.50
MAPK1 P28482 1/20 0.50
MAPT P10636 1/20 0.47
GPR84 Q9NQS5 4/20 0.43
FFAR1 O14842 1/20 0.43
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
SLC1A3 P43003 1/20 0.42
LCK P06239 1/20 0.42
PPARD Q03181 1/20 0.42
ZDHHC20 Q5W0Z9 1/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42
CHRM1 P11229 1/20 0.41
AKR1A1 P14550 1/20 0.41
CHRM3 P20309 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
DRD3 P35462 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539103 0.93 MAPT (0.55) CA2MAPK1MAPTGPR84FFAR1
SCHEMBL7207894 0.91 MAPT (0.59) CA2MAPTGPR84FFAR1SLC1A2
SCHEMBL527476 0.91 MAPT (0.59) CA2MAPTGPR84FFAR1SLC1A2
SCHEMBL970515 0.91 MAPT (0.59) CA2MAPTGPR84FFAR1SLC1A2
SCHEMBL10923278 0.91 MAPT (0.59) CA2MAPTGPR84FFAR1SLC1A2
SCHEMBL4002470 0.91 MAPT (0.59) CA2MAPTGPR84FFAR1SLC1A2
SCHEMBL3127134 0.86
SCHEMBL14764484 0.82 CA2 (0.40) CA2MAPK1MAPTGPR84FFAR1
SCHEMBL8014886 0.80 CA2 (0.52) CA2MAPK1MAPTGPR84SLC1A2
SCHEMBL316535 0.80 CA2 (0.48) CA2MAPK1MAPTGPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF Yamaguchi, Koushi (JP) 2023-04-06 US disclosed
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof Yamaguchi, Kouchi (JP) 2023-01-03 US disclosed
EP-3977995-A1 TACROLIMUS FOR AMELIORATING PREGNANCY CONDITIONS Yamaguchi, Koushi (JP) 2022-04-06 EP disclosed
EP-3900729-A1 AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCY Yamaguchi, Koushi (JP) 2021-10-27 EP disclosed
EP-3246036-B1 MEDICINE FOR IMPROVING PREGNANCY-INDUCED HYPERTENSION SYNDROME YAMAGUCHI KOUSHI (JP) 2021-10-13 EP disclosed
CN-113226331-A Medicine for improving infertility or pregnancy state 山口晃史 2021-08-06 CN disclosed
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP YAMAGUCHI KOUSHI (JP) 2021-07-29 US disclosed
EP-3834826-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNO-FETAL RELATIONSHIP Yamaguchi, Koushi (JP) 2021-06-16 EP disclosed
CN-112533599-A Therapeutic agent for humoral immunity-related diseases in maternal-fetal relationship 山口晃史 2021-03-19 CN disclosed
CN-107106588-B Agent for improving pregnancy status and use thereof 山口晃史 2020-08-11 CN disclosed
EP-0406791-A2 Aqueous liquid composition for external use FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-01-09 EP disclosed
EP-0399579-A1 Macrolides having immunosuppressive activity MERCK & CO. INC. (US) 1990-11-28 EP disclosed
EP-0388909-A2 Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-09-26 EP disclosed
US-4956352-A TREATING AUTOIMMUNE DISEASES, RESISTANCE TO TRANSPLANTATION, INFECTIONS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-09-11 US disclosed
US-4929611-A ANTIBODY INHIBITORS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-29 US disclosed
US-4894366-A Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-01-16 US disclosed
EP-0051467-B1 HEXITOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1986-08-13 EP disclosed
EP-0184162-A2 Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-06-11 EP disclosed
US-4419522-A ANTITUMOR AGENTS CHINOIN GYOGYSZER VEGYESZETI TERMEKEK GYARA RT. (HU) 1983-12-06 US disclosed
EP-0051467-A1 Hexitol derivatives, their preparation and pharmaceutical compositions containing them CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1982-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103337-A1 MEDICINE FOR IMPROVING STATE OF PREGNANCY, AND USE THEREOF PGF, SLC10A1, SLC26A4 CA2 573/4885MAPK1 1495/4885MAPT 4037/4885
US-11541040-B2 Medicine for improving state of pregnancy, and use thereof PGF, SLC10A1, SLC26A4 CA2 490/4885MAPK1 1303/4885MAPT 4108/4885
US-20210228551-A1 THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN MATERNOFETAL RELATIONSHIP PGF, HAMP, HLA-DRB1 CA2 2370/4885MAPK1 905/4885MAPT 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.